Analytical Data
-
Gene name
PE-Labeled HLA-A*02:01&B2M&HPV16 E7(YMLDLQPET) Monomer
- Application
-
Alternative Names
rHuHLA-A*0201 HPV16 E7 complex Protein; YMLDLQPET
-
Species
Human
-
Source
HEK293
-
Tag
C-His;C-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&YMLDLQPET
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The PE-Labeled HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) monomer recombinant protein is an important tool in the study of immune responses against human papillomavirus (HPV) which is implicated in various cancers, particularly cervical cancer. Human leukocyte antigen (HLA) molecules, such as HLA-A*02:01, play a critical role in presenting viral peptides to CD8+ T cells, thereby triggering an immune response. The integration of β2-microglobulin (B2M) is essential for the stable expression and presentation of the HLA-A*02:01 molecule. The specific peptide YMLDLQPET derived from the HPV16 E7 protein is known to be a dominant target for T cell recognition in individuals who express this HLA type. The development of a PE-labeled version of this recombinant protein facilitates the identification and characterization of E7-specific T cells, enabling researchers to analyze T cell responses in the context of HPV infection and tumorigenesis. Such studies provide valuable insights into the mechanisms of immune evasion by cancer cells and contribute to the design of targeted immunotherapies and vaccines aimed at eliciting robust antitumor immune responses. Overall, the PE-Labeled HLA-A*02:01&B2M&HPV16 E7 monomer holds significant potential for advancing our understanding of HPV-associated malignancies and improving therapeutic interventions.
